Monument Therapeutics
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Monument Therapeutics firmographics
Firmographics- Name
- Monument Therapeutics
- Legal name
- Monument Therapeutics Limited
- Website
- https://monumenttx.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Monument Therapeutics industry classification
Industry- Product category
- CNS Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Monument Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Monument Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Drug Development: Developing novel CNS therapeutics through clinical development toward regulatory approval and commercialization. Revenue will be generated through product sales or licensing agreements upon successful development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Monument Therapeutics product offering
Product offeringCore offering
Monument Therapeutics is a clinical-stage biotech developing two CNS drug programs: MT1988, a fixed-dose combination of tropisetron and varenicline for cognitive impairment associated with schizophrenia (CIAS), and MT1980, a LipiCore-formulated anti-inflammatory compound for neuroinflammation conditions including Alzheimer's disease, post-operative cognitive dysfunction, and Long COVID. The company pairs these drug candidates with proprietary digital cognitive biomarkers (latent inhibition) and licensed CANTAB assessments to stratify patients and match them to targeted treatments.
Product overview
Monument Therapeutics is a UK clinical-stage biotech company developing a pipeline of two core drug treatments for psychiatric and neurological conditions. The lead program MT1988 is a fixed-dose combination of tropisetron and varenicline targeting cognitive impairment associated with schizophrenia, using proprietary digital biomarkers for patient stratification. The second program MT1980 is an anti-neuroinflammatory compound using licensed LipiCore drug delivery technology for neuroinflammation-related conditions. The company leverages proprietary cognitive assessment tools (including latent inhibition tasks) alongside licensed CANTAB assessments from Cambridge Cognition to match patients with targeted treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- MT1988 MT1988 is a novel fixed-dose combination of tropisetron (α7 nAChR partial agonist, 5-HT3 antagonist) and varenicline (α7/α4β2 agonist, 5-HT3 agonist) being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS). Designed to enhance cognitive function while counteracting peripheral GI side effects, MT1988 is intended for use alongside existing antipsychotic medications. Patient selection is guided by Monument's proprietary latent-inhibition digital cognitive biomarker. Composition-of-matter patents are granted in the US, UK, Japan, and China with exclusivity extending to 2040-2042.
- MT1980 MT1980 is a lipid-based reformulation of an on-market anti-inflammatory compound using LipiCore drug delivery technology licensed from TRx Biosciences. The LipiCore formulation is designed to enable the compound to cross the blood-brain barrier, addressing penetration limitations of standard formulations. MT1980 is being developed for neuroinflammation-associated indications including Alzheimer's disease, post-operative cognitive dysfunction (POCD), stroke, traumatic brain injury, depression, and Long COVID. UK patent protection extends to at least 2044.
Companies that use Monument Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Monument Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Monument Therapeutics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered program, flagship, clinical trial and core.
- One Mind AcceleratorprogramSelected for 2026 One Mind Accelerator cohort (4th cohort since 2023) focused on mental health innovation with less than 5% acceptance rate. Prior portfolio companies raised nearly $1 billion and impacted 1 million people since Demo Day.
- Foundation for the National Institutes of Health (FNIH)flagshipPartnership with FNIH to evaluate MT1988 in proof-of-principle clinical trial as part of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. Trial enrolls 150 CHR participants at 15 US sites over 8-week treatment period, evaluating cognitive symptoms and biomarkers including proprietary digital biomarker. Supported by NIH grants to Yale and Brigham and Women's Hospital totaling $44 million.
- BDD Pharmaclinical trialPhase I clinical trial Principal Investigator site for MT1988 evaluation of safety, tolerability and pharmacokinetics in healthy adults.
- TRx BiosciencescoreLicensed LipiCore targeted oral drug delivery technology for MT1980 to solve blood-brain barrier penetration limitations. Technology enables anti-inflammatory compounds to access the CNS for neuroinflammation treatment.
- University of NottinghamcorePreclinical collaboration for MT1988 program with School of Psychology including Professor Claire Gibson and Dr Stuart Williams. Provided preclinical proof of mechanism evidence for biomarker and drug combination prior to clinical trials.
- Cambridge CognitioncoreSpin-out from Cambridge Cognition with minority shareholding retained. Licensed gold-standard cognitive assessments including CANTAB for patient stratification. Monument commercializes digital biomarkers across neuroscience indications with Cambridge Cognition retaining IP.
Scale indicators4 records
Recent moves7 records
Expansion highlights7 records
Monument Therapeutics competitors and assessment
Company assessmentDirect peers
- BlackThorn Therapeutics: Precision neuroscience company applying computational approaches and digital biomarkers to CNS drug development, with programs in depression and other psychiatric conditions. Directly comparable precision psychiatry approach using patient stratification.
- Alto Neuroscience: Clinical-stage precision psychiatry company using biomarkers (including EEG and digital measures) to stratify patients and match them with targeted CNS therapeutics, including for schizophrenia. Most directly comparable to Monument on the digital biomarker + targeted CNS drug model.
- Karuna Therapeutics: Developed xanomeline-trospium (Cobenfy) for schizophrenia, approved 2024 and acquired by Bristol Myers Squibb. Directly comparable CNS precision therapeutics company that successfully advanced a targeted schizophrenia therapy through pivotal trials.
- Sage Therapeutics: CNS-focused company developing therapeutics for schizophrenia, depression, and other brain disorders (Zurzuvae, collaboration with Biogen). Directly comparable specialty CNS biotech with late-stage clinical pipeline.
- Cerevel Therapeutics: Precision neuroscience company (acquired by AbbVie in 2024 for ~$8.7B) with a pipeline including emraclidine for schizophrenia. Directly comparable CNS precision therapeutics developer targeting similar patient subpopulations.
- Neumora Therapeutics: Clinical-stage precision neuroscience company developing targeted therapies for brain diseases using data-driven patient stratification. Closely aligned with Monument's biomarker-driven precision psychiatry thesis.
Emerging players
- Compass Pathways: Clinical-stage mental health company developing psilocybin-based therapeutics for treatment-resistant depression and other psychiatric conditions. Comparable as a CNS-focused clinical-stage biotech pursuing novel mechanisms in psychiatry.
Broad incumbents
- Acadia Pharmaceuticals: Established commercial CNS specialty pharma (Nuplazid, Daybue) with schizophrenia and neurology pipeline. Provides an incumbent comparison point for Monument's specialty CNS commercial pathway.
- Intra-Cellular Therapies: CNS specialty pharma (Caplyta/lumateperone for schizophrenia and bipolar depression, acquired by J&J in 2025). Established specialty CNS player operating in Monument's target indications.
- Boehringer Ingelheim (CNS): Large pharmaceutical company with active CNS pipeline including schizophrenia programs (e.g., iclepertin for CIAS) and is a potential strategic acquirer / licensing partner for clinical-stage CNS assets like Monument's MT1988.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Monument Therapeutics social profiles
Digital presenceMonument Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Monument Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Monument Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Monument Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Monument Therapeutics
What does Monument Therapeutics do?
Monument Therapeutics is a clinical-stage biotech developing two CNS drug programs: MT1988, a fixed-dose combination of tropisetron and varenicline for cognitive impairment associated with schizophrenia (CIAS), and MT1980, a LipiCore-formulated anti-inflammatory compound for neuroinflammation conditions including Alzheimer's disease, post-operative cognitive dysfunction, and Long COVID. The company pairs these drug candidates with proprietary digital cognitive biomarkers (latent inhibition) and licensed CANTAB assessments to stratify patients and match them to targeted treatments.
Is Monument Therapeutics a public or private company?
Monument Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Monument Therapeutics founded?
Monument Therapeutics was founded in 2021. It employs 1 to 10 people.
Where is Monument Therapeutics based?
Monument Therapeutics is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Monument Therapeutics make money?
One revenue line is on record: pharmaceutical Drug Development.
Who are Monument Therapeutics's main competitors?
Direct peers on record are BlackThorn Therapeutics, Alto Neuroscience, Karuna Therapeutics, Sage Therapeutics, Cerevel Therapeutics and Neumora Therapeutics. Compass Pathways is listed as an emerging player. Broad incumbents are Acadia Pharmaceuticals, Intra-Cellular Therapies and Boehringer Ingelheim (CNS).
Does Monument Therapeutics have an API?
No public API is recorded for Monument Therapeutics.
What industry is Monument Therapeutics in?
Monument Therapeutics's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 541714 and its SIC code is 8731.